-
1 Comment
Reckitt Benckiser Group plc is currently in a long term uptrend where the price is trading 0.6% above its 200 day moving average.
From a valuation standpoint, the stock is 97.0% cheaper than other stocks from the Consumer Defensive sector with a price to sales ratio of 3.4.
Finally, its free cash flow fell by 40.8% to $602M since the same quarter in the previous year.
Based on the above factors, Reckitt Benckiser Group plc gets an overall score of 2/5.
Sector | Consumer Defensive |
---|---|
Exchange | F |
CurrencyCode | EUR |
Industry | Household & Personal Products |
ISIN | GB00B24CGK77 |
Beta | 0.17 |
---|---|
Market Cap | 38B |
PE Ratio | 23.42 |
Target Price | None |
Dividend Yield | 4.1% |
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products in the United Kingdom and internationally. The company offers germ protection under Dettol name; intimate wellness under Durex and KY brand names; over the counter under the Biofreeze, Gaviscon, Mucinex, Nurofen, and Strepsils names. It also provides personal care products under Clearasil and Veet brand names; vitamins, minerals, and supplements under Airborne, Movefree, and neuriva names; and disinfectant products under the Finish, Harpic, and Lysol brands. In addition, the company offers nutritious complementary foods and milk formulas for infant and young children under the Enfamil and Nutramigen brands. Reckitt Benckiser Group plc was founded in 1819 and is headquartered in Slough, the United Kingdom.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 3RB.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025